G

    Gyre Therapeutics Inc. (GYRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.57
    -0.02 (-0.30%)

    Market Cap: $696.64M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    22%(8/37)
    Avg Surprise
    -1289.57%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.12
    Range$-0.19 - $-0.06
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$-0.07+37.2%
    60d ago$-0.07+37.2%
    30d ago$-0.07+37.2%
    7d ago$-0.07+37.2%
    Current$-0.12
    Revenue Consensus
    $28M
    Range$28M - $29M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.36 - $0.03
    3 analysts
    Revenue Consensus
    $23M
    Range$22M - $24M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-$-0.12---
    Jun 26
    Reported Aug 7
    		$-0.12$-0.08-50.00%Miss-5554.5%
    Mar 26
    Reported May 7
    		$-0.10$-0.07-42.86%Miss-2425.6%
    Dec 25
    Reported Mar 12
    		$0.05$0.05+0.21%Beat+4354.5%
    Sep 25
    Reported Nov 7
    		$0.03$-0.02+250.00%Beat+129.0%
    Jun 25
    Reported Aug 11
    		$0.00N/A-92.67%Miss-93.5%
    Mar 25
    Reported May 9
    		$0.00N/A-85.67%Miss-86.4%
    Dec 24
    Reported Mar 17
    		$-0.00N/A-102.75%Miss-
    Sep 24
    Reported Nov 13
    		$0.01N/AN/ABeat+101.2%
    Jun 24
    Reported Aug 13
    		$0.03N/AN/ABeat+103.2%
    Mar 24
    Reported May 9
    		$0.03$0.00N/ABeat-78.9%
    Dec 23
    Reported Mar 26
    		$0.00N/A+100.00%Beat+100.0%
    Sep 23
    Reported Oct 26
    		$-1.05$-0.75-40.00%Miss+56.3%
    Jun 23
    Reported Aug 14
    		$-1.05$-0.07-1400.00%Miss-104.3%
    Mar 23
    Reported May 15
    		$0.15$-0.07+314.29%Beat+102.2%
    Dec 22
    Reported Mar 30
    		$-19.05$-0.10-18042.86%Miss-95.4%
    Sep 22
    Reported Nov 14
    		$-2.40$-0.10-2300.00%Miss+80.0%
    Jun 22
    Reported Aug 15
    		$24.60$-0.24+10140.82%Beat+356.3%
    Mar 22
    Reported May 9
    		$-6.90$-0.46-1410.84%Miss+41.8%
    Dec 21
    Reported Mar 31
    		$-9.75$-0.59-1559.57%Miss+24.4%
    Sep 21
    Reported Nov 12
    		$-12.00$-0.66-1718.18%Miss-9.6%
    Jun 21
    Reported Aug 5
    		$-9.60$-0.69-1281.30%Miss+33.3%
    Mar 21
    Reported May 6
    		$-11.85$-0.58-1951.95%Miss-182.1%
    Dec 20
    Reported Mar 4
    		$-12.90$-0.86-1395.65%Miss+30.1%
    Sep 20
    Reported Nov 5
    		$-10.95$-0.81-1257.38%Miss+31.1%
    Jun 20
    Reported Aug 6
    		$-14.40$-0.86-1574.42%Miss+16.5%
    Mar 20
    Reported May 11
    		$-4.20$-0.37-1035.14%Miss+77.8%
    Dec 19
    Reported Feb 20
    		$-18.45$0.17-10952.94%Miss-35.2%
    Sep 19
    Reported Nov 7
    		$-15.90$-1.16-1270.69%Miss-65.6%
    Jun 19
    Reported Aug 1
    		$-17.25$-1.11-1454.05%Miss-113.0%
    Mar 19
    Reported May 2
    		$-18.90$-1.08-1650.00%Miss-125.0%
    Dec 18
    Reported Mar 8
    		$-13.65$-0.75-1720.00%Miss-992.0%
    Sep 18
    Reported Nov 1
    		$-9.60$-0.59-1527.12%Miss+52.2%
    Jun 18
    Reported Aug 2
    		$-8.10$-0.62-1206.45%Miss-432.9%
    Mar 18
    Reported May 3
    		$-8.40$-0.92-813.04%Miss-83.8%
    Dec 17
    Reported Mar 19
    		$-1.25$-1.53+18.30%Beat+73.1%
    Sep 17
    Reported Nov 2
    		$-20.10$-1.32-1422.73%Miss+77.7%
    Jun 17
    Reported Aug 3
    		$-1.52$-1.46-4.11%Miss-
    Mar 17
    Reported May 11
    		$-4.57$-6.10+25.08%Beat-
    Dec 16
    Reported Mar 8
    		$-4.65$-5.63+17.41%Beat-
    Sep 16
    Reported Nov 3
    		$-90.00$-6.83-1217.72%Miss-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    Payout Ratio0.00%

    Key Metrics

    Valuation
    P/E Ratio-45.88EV/EBITDA131.00x
    Price/FCF-41.98xFCF Yield-2.38%
    Profitability
    Profit Margin-19.30%Operating Margin-47.60%
    ROE-17.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-7.26x
    Current Ratio4.26xQuick Ratio3.86x
    Trading Statistics
    Beta4.82Avg Volume53.42K
    52-Week High$9.4252-Week Low$5.44

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.77
    SMA 20$6.66
    SMA 50$6.46
    SMA 200$7.17
    EMA 10$6.66
    EMA 20$6.61
    EMA 50$6.53
    EMA 200$7.10

    MACD

    Line: 0.09Signal: 0.12Hist: -0.03

    ADX

    ADX: 16.9+DI: 21.0-DI: 23.3

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down16.0
    PSAR$7.21

    Bollinger Bands

    Upper Band$7.15
    Lower Band$6.17
    %B Position1478%(Upper)
    Band Width0.41

    RSI (14-Day)

    Neutral
    50.1

    Momentum Oscillators

    Stoch %K24.2
    Stoch %D31.5
    Williams %R-83.7
    ROC (10d)-3.5%
    Momentum-0.24
    CCI (20d)-44.0
    MFI (14d)59.1

    Volatility Measures

    ATR (14d)$0.29(4.5%)
    StdDev (20d)0.25
    Hist Vol39.6%(Moderate)

    Volume Flow

    VWAP$6.55
    OBV-1.9M
    AD Line-7.0M
    CMF (20d)-0.019

    Volume Metrics

    Avg Vol (20d)53.4K
    Vol Ratio0.8x
    VWMA (20d)$6.68

    Pivot Points

    R3$6.84
    R2$6.77
    R1$6.68
    Pivot Point$6.61
    S1$6.52
    S2$6.45
    S3$6.36

    Advanced Oscillators

    TSI8.21
    Ultimate Osc39.9
    KST75.93

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$29.11M$22.52M$37.20M$30.56M$29.73M$22.06M$27.87M$25.49M$25.23M$27.17M$27.15M$32.04M
    Cost of Revenue$2.21M$1.23M$1.74M$1.63M$1.15M$894,000$1.18M$958,000$770,000$979,000$1.25M$1.18M
    Gross Profit$26.90M$21.29M$35.45M$28.94M$28.58M$21.16M$26.70M$24.53M$24.45M$26.19M$25.90M$30.86M
    Operating Expenses$41.26M$30.65M$35.33M$22.01M$30.82M$18.89M$26.03M$20.30M$21.26M$18.12M$117.00M$18.62M
    R&D$19.14M$6.74M$4.82M$2.36M$8.35M$3.10M$3.71M$2.77M$3.35M$2.18M$87.67M$3.01M
    SG&A$7.87M$7.22M$6.70M$4.32M$7.28M$4.96M$5.46M$3.82M$3.42M$3.40M$10.05M$1.16M
    Operating Income$-14,363,000$-9,355,000$118,000$6.92M$-2,240,000$2.27M$665,000$4.23M$3.19M$8.07M$-91,632,000$12.76M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-740,000$0$184,000$0$-941,000$0$0$303,000$0$0$-326,000$-283,000
    Income Before Tax$-14,434,000$-9,237,000$-66,000$7.63M$-1,575,000$4.63M$772,000$3.93M$6.04M$12.48M$-100,278,000$11.19M
    Income Tax Expense$-164,000$621,000$1.30M$1.69M$662,000$901,000$203,000$1.07M$1.50M$2.55M$699,000$3.68M
    Net Income$-14,270,000$-9,858,000$-1,366,000$5.94M$-2,237,000$3.73M$569,000$2.86M$4.54M$9.94M$-100,977,000$7.51M
    EBITDA$-13,691,000$-8,565,000$-1,157,000$8.28M$-1,507,000$5.17M$-314,000$4.38M$6.26M$12.90M$-100,822,000$11.63M
    EBIT$-15,174,000$-9,237,000$-1,813,000$7.63M$-2,516,000$4.63M$-775,000$3.93M$6.04M$12.48M$-101,130,000$11.43M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GYRE

    News

    Gyre Therapeutics (NASDAQ:GYRE) Lowered to "Strong Sell" Rating by Zacks Research

    Zacks Research downgraded Gyre Therapeutics (NASDAQ:GYRE) from a "hold" to a "strong sell" rating, with other firms also issuing negative ratings, though the overall analyst consensus remains "hold" with a $17 target price. The company reported a quarterly loss of $0.12 per share, missing estimates, despite revenue exceeding expectations. Institutional investors and hedge funds own 23.99% of the shares, with several increasing their holdings in the second quarter.

    MarketBeat•8/20/26•
    Bearish

    Analysts Set Expectations for GYRE Q3 Earnings

    Noble Financial has forecasted that Gyre Therapeutics (NASDAQ:GYRE) will report a Q3 2026 loss of $0.10 per share, with a full-year consensus estimate of a $0.30 loss per share. This follows a recent quarter where the company missed EPS expectations but exceeded revenue estimates. Gyre Therapeutics currently holds a consensus "Hold" rating from analysts, with a target price of $17, while its shares recently traded at $6.98.

    MarketBeat•8/19/26•
    Somewhat-Bearish

    GYRE | Gyre Therapeutics, Inc. Common Financials - Revenue Breakdown

    This page provides a detailed financial overview of Gyre Therapeutics, Inc. (GYRE), focusing on its revenue breakdown and other key financial metrics. It includes sections on insider trading, institutional holdings, analyst ratings, and a company overview, but notes that specific revenue breakdown data by segment or geography is currently unavailable. The article also highlights the company's focus on developing therapies for organ fibrosis and inflammatory diseases.

    Quiver Quantitative•8/19/26•
    Neutral

    Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20

    Noble Financial has reiterated its Buy rating for Gyre Therapeutics (GYRE.US) and maintained a target price of $20. This indicates a continued positive outlook from the firm regarding the company's stock performance.

    Moomoo•8/10/26•
    Bullish

    Thin Float, Heavy Overhang: Analyst Warns Gyre Therapeutics’ Concentrated Ownership and Pledged Shares Heighten Liquidity and Control Risks

    An analyst has issued a warning regarding Gyre Therapeutics Inc. (GYRE), citing its thinly traded common stock and concentrated ownership as significant risks. This structure heightens liquidity concerns, as any large share sale could drastically impact the stock price, and the pledging of shares for a loan introduces further overhang risk through potential foreclosure and change of control. Wall Street currently maintains a Moderate Buy consensus on GYRE, based on one Buy rating.

    TipRanks•8/10/26•
    Bearish

    Frequently Asked Questions About GYRE

    Does GYRE pay dividends?
    Gyre Therapeutics Inc. (GYRE) has a dividend payment track record. See the GYRE dividend history page for its current payment status, yield, and streaks.
    What is GYRE's market cap?
    Gyre Therapeutics Inc. (GYRE) has a market capitalization of $696.64M with a current stock price of $6.57.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In